Physician profile
Maeghan Smith
NPI 1871256743
$11,673.45
in general payments reported to CMS, 2019-2025
45 companies · $3,048 in 2025
The $3,048 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34.63 · 2022: $2,434 · 2023: $2,791 · 2024: $3,366 · 2025: $3,048.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,990 · Education: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,990.36 |
| Education | $214.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,422.11 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,267.92 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,243.99 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $833.37 | 2022-2025 | |
| Glaxosmithkline, LLC. | $672.97 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $649.93 | 2022-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $630.91 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $518.79 | 2022-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $421.41 | 2021-2024 | Xarelto |
| Esperion Therapeutics, INC. | $401.89 | 2022-2025 | Nexletol |
| Pfizer INC. | $374.20 | 2023-2025 | |
| Idorsia Pharmaceuticals US INC | $326.23 | 2022-2025 | Quviviq, Quviviq |
| Merck Sharp & Dohme LLC | $264.07 | 2022-2025 | Verquvo, Capvaxive, Steglatro |
| Novartis Pharmaceuticals Corporation | $257.74 | 2022-2024 | |
| Exact Sciences Corporation | $253.28 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maeghan Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.